Skip to main content
Top
Published in: Thrombosis Journal 1/2014

Open Access 01-12-2014 | Original basic research

Paxillin is an intrinsic negative regulator of platelet activation in mice

Authors: Asuka Sakata, Tsukasa Ohmori, Satoshi Nishimura, Hidenori Suzuki, Seiji Madoiwa, Jun Mimuro, Kazuomi Kario, Yoichi Sakata

Published in: Thrombosis Journal | Issue 1/2014

Login to get access

Abstract

Background

Paxillin is a LIM domain protein localized at integrin-mediated focal adhesions. Although paxillin is thought to modulate the functions of integrins, little is known about the contribution of paxillin to signaling pathways in platelets. Here, we studied the role of paxillin in platelet activation in vitro and in vivo.

Methods and results

We generated paxillin knockdown (Pxn-KD) platelets in mice by transplanting bone marrow cells transduced with a lentiviral vector carrying a short hairpin RNA sequence, and confirmed that paxillin expression was significantly reduced in platelets derived from the transduced cells. Pxn-KD platelets showed a slight increased in size and augmented integrin αIIbβ3 activation following stimulation of multiple receptors including glycoprotein VI and G protein-coupled receptors. Thromboxane A2 biosynthesis and the release of α-granules and dense granules in response to agonist stimulation were also enhanced in Pxn-KD platelets. However, Pxn-KD did not increase tyrosine phosphorylation or intracellular calcium mobilization. Intravital imaging confirmed that Pxn-KD enhanced thrombus formation in vivo.

Conclusions

Our findings suggest that paxillin negatively regulates several common platelet signaling pathways, resulting in the activation of integrin αIIbβ3 and release reactions.
Appendix
Available only for authorised users
Literature
2.
go back to reference Watson SP, Auger JM, McCarty OJ, Pearce AC: GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost. 2005, 3: 1752-1762. 10.1111/j.1538-7836.2005.01429.x.CrossRefPubMed Watson SP, Auger JM, McCarty OJ, Pearce AC: GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost. 2005, 3: 1752-1762. 10.1111/j.1538-7836.2005.01429.x.CrossRefPubMed
3.
go back to reference Varga-Szabo D, Pleines I, Nieswandt B: Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008, 28: 403-412. 10.1161/ATVBAHA.107.150474.CrossRefPubMed Varga-Szabo D, Pleines I, Nieswandt B: Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008, 28: 403-412. 10.1161/ATVBAHA.107.150474.CrossRefPubMed
4.
5.
go back to reference Siess W: Molecular mechanisms of platelet activation. Physiol Rev. 1989, 69: 58-178.PubMed Siess W: Molecular mechanisms of platelet activation. Physiol Rev. 1989, 69: 58-178.PubMed
6.
7.
go back to reference Moser M, Legate KR, Zent R, Fassler R: The tail of integrins, talin, and kindlins. Science. 2009, 324: 895-899. 10.1126/science.1163865.CrossRefPubMed Moser M, Legate KR, Zent R, Fassler R: The tail of integrins, talin, and kindlins. Science. 2009, 324: 895-899. 10.1126/science.1163865.CrossRefPubMed
8.
go back to reference Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R: Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008, 14: 325-330. 10.1038/nm1722.CrossRefPubMed Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R: Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008, 14: 325-330. 10.1038/nm1722.CrossRefPubMed
9.
go back to reference Nieswandt B, Moser M, Pleines I, Varga-Szabo D, Monkley S, Critchley D, Fassler R: Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med. 2007, 204: 3113-3118. 10.1084/jem.20071827.PubMedCentralCrossRefPubMed Nieswandt B, Moser M, Pleines I, Varga-Szabo D, Monkley S, Critchley D, Fassler R: Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med. 2007, 204: 3113-3118. 10.1084/jem.20071827.PubMedCentralCrossRefPubMed
10.
go back to reference Petrich BG, Fogelstrand P, Partridge AW, Yousefi N, Ablooglu AJ, Shattil SJ, Ginsberg MH: The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation. J Clin Invest. 2007, 117: 2250-2259. 10.1172/JCI31024.PubMedCentralCrossRefPubMed Petrich BG, Fogelstrand P, Partridge AW, Yousefi N, Ablooglu AJ, Shattil SJ, Ginsberg MH: The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation. J Clin Invest. 2007, 117: 2250-2259. 10.1172/JCI31024.PubMedCentralCrossRefPubMed
11.
go back to reference Cantor JM, Ginsberg MH, Rose DM: Integrin-associated proteins as potential therapeutic targets. Immunol Rev. 2008, 223: 236-251. 10.1111/j.1600-065X.2008.00640.x.CrossRefPubMed Cantor JM, Ginsberg MH, Rose DM: Integrin-associated proteins as potential therapeutic targets. Immunol Rev. 2008, 223: 236-251. 10.1111/j.1600-065X.2008.00640.x.CrossRefPubMed
12.
go back to reference Glenney JR, Zokas L: Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol. 1989, 108: 2401-2408. 10.1083/jcb.108.6.2401.CrossRefPubMed Glenney JR, Zokas L: Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol. 1989, 108: 2401-2408. 10.1083/jcb.108.6.2401.CrossRefPubMed
13.
go back to reference Brown MC, Turner CE: Paxillin: adapting to change. Physiol Rev. 2004, 84: 1315-1339. 10.1152/physrev.00002.2004.CrossRefPubMed Brown MC, Turner CE: Paxillin: adapting to change. Physiol Rev. 2004, 84: 1315-1339. 10.1152/physrev.00002.2004.CrossRefPubMed
15.
go back to reference Hagmann J, Grob M, Welman A, Van Willigen G, Burger MM: Recruitment of the LIM protein hic-5 to focal contacts of human platelets. J Cell Sci. 1998, 111 (Pt 15): 2181-2188.PubMed Hagmann J, Grob M, Welman A, Van Willigen G, Burger MM: Recruitment of the LIM protein hic-5 to focal contacts of human platelets. J Cell Sci. 1998, 111 (Pt 15): 2181-2188.PubMed
16.
go back to reference Osada M, Ohmori T, Yatomi Y, Satoh K, Hosogaya S, Ozaki Y: Involvement of Hic-5 in platelet activation: integrin alphaIIbbeta3-dependent tyrosine phosphorylation and association with proline-rich tyrosine kinase 2. Biochem J. 2001, 355: 691-697.PubMedCentralCrossRefPubMed Osada M, Ohmori T, Yatomi Y, Satoh K, Hosogaya S, Ozaki Y: Involvement of Hic-5 in platelet activation: integrin alphaIIbbeta3-dependent tyrosine phosphorylation and association with proline-rich tyrosine kinase 2. Biochem J. 2001, 355: 691-697.PubMedCentralCrossRefPubMed
17.
go back to reference Rathore VB, Okada M, Newman PJ, Newman DK: Paxillin family members function as Csk-binding proteins that regulate Lyn activity in human and murine platelets. Biochem J. 2007, 403: 275-281. 10.1042/BJ20061618.PubMedCentralCrossRefPubMed Rathore VB, Okada M, Newman PJ, Newman DK: Paxillin family members function as Csk-binding proteins that regulate Lyn activity in human and murine platelets. Biochem J. 2007, 403: 275-281. 10.1042/BJ20061618.PubMedCentralCrossRefPubMed
18.
go back to reference Liu S, Slepak M, Ginsberg MH: Binding of Paxillin to the alpha 9 integrin cytoplasmic domain inhibits cell spreading. J Biol Chem. 2001, 276: 37086-37092. 10.1074/jbc.M105114200.CrossRefPubMed Liu S, Slepak M, Ginsberg MH: Binding of Paxillin to the alpha 9 integrin cytoplasmic domain inhibits cell spreading. J Biol Chem. 2001, 276: 37086-37092. 10.1074/jbc.M105114200.CrossRefPubMed
19.
go back to reference Liu S, Thomas SM, Woodside DG, Rose DM, Kiosses WB, Pfaff M, Ginsberg MH: Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature. 1999, 402: 676-681. 10.1038/45264.CrossRefPubMed Liu S, Thomas SM, Woodside DG, Rose DM, Kiosses WB, Pfaff M, Ginsberg MH: Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature. 1999, 402: 676-681. 10.1038/45264.CrossRefPubMed
20.
go back to reference Coller BS, Anderson K, Weisman HF: New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995, 74: 302-308.PubMed Coller BS, Anderson K, Weisman HF: New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995, 74: 302-308.PubMed
21.
go back to reference Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Sakata Y: Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence. Arterioscler Thromb Vasc Biol. 2007, 27: 2266-2272. 10.1161/ATVBAHA.107.149872.CrossRefPubMed Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Sakata Y: Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence. Arterioscler Thromb Vasc Biol. 2007, 27: 2266-2272. 10.1161/ATVBAHA.107.149872.CrossRefPubMed
22.
go back to reference Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Ihrig MM, McManus MT, Gertler FB, et al: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003, 33: 401-406. 10.1038/ng1117.CrossRefPubMed Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Ihrig MM, McManus MT, Gertler FB, et al: A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet. 2003, 33: 401-406. 10.1038/ng1117.CrossRefPubMed
23.
go back to reference Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Furukawa Y, Sakata Y: Vinculin is indispensable for repopulation by hematopoietic stem cells, independent of integrin function. J Biol Chem. 2010, 285: 31763-31773. 10.1074/jbc.M109.099085.PubMedCentralCrossRefPubMed Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Furukawa Y, Sakata Y: Vinculin is indispensable for repopulation by hematopoietic stem cells, independent of integrin function. J Biol Chem. 2010, 285: 31763-31773. 10.1074/jbc.M109.099085.PubMedCentralCrossRefPubMed
24.
go back to reference Suzuki H, Okamura Y, Ikeda Y, Takeoka S, Handa M: Ultrastructural analysis of thrombin-induced interaction between human platelets and liposomes carrying fibrinogen gamma-chain dodecapeptide as a synthetic platelet substitute. Thromb Res. 2011, 128: 552-559. 10.1016/j.thromres.2011.07.031.CrossRefPubMed Suzuki H, Okamura Y, Ikeda Y, Takeoka S, Handa M: Ultrastructural analysis of thrombin-induced interaction between human platelets and liposomes carrying fibrinogen gamma-chain dodecapeptide as a synthetic platelet substitute. Thromb Res. 2011, 128: 552-559. 10.1016/j.thromres.2011.07.031.CrossRefPubMed
25.
go back to reference Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B: Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry. 2002, 48: 80-86. 10.1002/cyto.10114.CrossRefPubMed Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B: Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry. 2002, 48: 80-86. 10.1002/cyto.10114.CrossRefPubMed
26.
go back to reference Nishimura S, Manabe I, Nagasaki M, Kakuta S, Iwakura Y, Takayama N, Ooehara J, Otsu M, Kamiya A, Petrich BG, et al: In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood. 2012, 119: e45-e56. 10.1182/blood-2011-09-381400.PubMedCentralCrossRefPubMed Nishimura S, Manabe I, Nagasaki M, Kakuta S, Iwakura Y, Takayama N, Ooehara J, Otsu M, Kamiya A, Petrich BG, et al: In vivo imaging visualizes discoid platelet aggregations without endothelium disruption and implicates contribution of inflammatory cytokine and integrin signaling. Blood. 2012, 119: e45-e56. 10.1182/blood-2011-09-381400.PubMedCentralCrossRefPubMed
27.
go back to reference Smolenski A: Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost. 2012, 10: 167-176. 10.1111/j.1538-7836.2011.04576.x.CrossRefPubMed Smolenski A: Novel roles of cAMP/cGMP-dependent signaling in platelets. J Thromb Haemost. 2012, 10: 167-176. 10.1111/j.1538-7836.2011.04576.x.CrossRefPubMed
28.
go back to reference Ming Z, Hu Y, Xiang J, Polewski P, Newman PJ, Newman DK: Lyn and PECAM-1 function as interdependent inhibitors of platelet aggregation. Blood. 2011, 117: 3903-3906. 10.1182/blood-2010-09-304816.PubMedCentralCrossRefPubMed Ming Z, Hu Y, Xiang J, Polewski P, Newman PJ, Newman DK: Lyn and PECAM-1 function as interdependent inhibitors of platelet aggregation. Blood. 2011, 117: 3903-3906. 10.1182/blood-2010-09-304816.PubMedCentralCrossRefPubMed
29.
go back to reference Wong C, Liu Y, Yip J, Chand R, Wee JL, Oates L, Nieswandt B, Reheman A, Ni H, Beauchemin N, Jackson DE: CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo. Blood. 2009, 113: 1818-1828. 10.1182/blood-2008-06-165043.CrossRefPubMed Wong C, Liu Y, Yip J, Chand R, Wee JL, Oates L, Nieswandt B, Reheman A, Ni H, Beauchemin N, Jackson DE: CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo. Blood. 2009, 113: 1818-1828. 10.1182/blood-2008-06-165043.CrossRefPubMed
30.
go back to reference Signarvic RS, Cierniewska A, Stalker TJ, Fong KP, Chatterjee MS, Hess PR, Ma P, Diamond SL, Neubig RR, Brass LF: RGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injury. Blood. 2010, 116: 6092-6100. 10.1182/blood-2010-05-283846.PubMedCentralCrossRefPubMed Signarvic RS, Cierniewska A, Stalker TJ, Fong KP, Chatterjee MS, Hess PR, Ma P, Diamond SL, Neubig RR, Brass LF: RGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injury. Blood. 2010, 116: 6092-6100. 10.1182/blood-2010-05-283846.PubMedCentralCrossRefPubMed
31.
go back to reference Hagel M, George EL, Kim A, Tamimi R, Opitz SL, Turner CE, Imamoto A, Thomas SM: The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling. Mol Cell Biol. 2002, 22: 901-915. 10.1128/MCB.22.3.901-915.2002.PubMedCentralCrossRefPubMed Hagel M, George EL, Kim A, Tamimi R, Opitz SL, Turner CE, Imamoto A, Thomas SM: The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling. Mol Cell Biol. 2002, 22: 901-915. 10.1128/MCB.22.3.901-915.2002.PubMedCentralCrossRefPubMed
32.
go back to reference Feral CC, Rose DM, Han J, Fox N, Silverman GJ, Kaushansky K, Ginsberg MH: Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J Clin Invest. 2006, 116: 715-723. 10.1172/JCI26091.PubMedCentralCrossRefPubMed Feral CC, Rose DM, Han J, Fox N, Silverman GJ, Kaushansky K, Ginsberg MH: Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J Clin Invest. 2006, 116: 715-723. 10.1172/JCI26091.PubMedCentralCrossRefPubMed
33.
go back to reference Dorsam RT, Kim S, Jin J, Kunapuli SP: Coordinated signaling through both G12/13 and G (i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem. 2002, 277: 47588-47595. 10.1074/jbc.M208778200.CrossRefPubMed Dorsam RT, Kim S, Jin J, Kunapuli SP: Coordinated signaling through both G12/13 and G (i) pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem. 2002, 277: 47588-47595. 10.1074/jbc.M208778200.CrossRefPubMed
34.
go back to reference Nieswandt B, Schulte V, Zywietz A, Gratacap MP, Offermanns S: Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets. J Biol Chem. 2002, 277: 39493-39498. 10.1074/jbc.M207256200.CrossRefPubMed Nieswandt B, Schulte V, Zywietz A, Gratacap MP, Offermanns S: Costimulation of Gi- and G12/G13-mediated signaling pathways induces integrin alpha IIbbeta 3 activation in platelets. J Biol Chem. 2002, 277: 39493-39498. 10.1074/jbc.M207256200.CrossRefPubMed
35.
go back to reference Gupta S, Braun A, Morowski M, Premsler T, Bender M, Nagy Z, Sickmann A, Hermanns HM, Bosl M, Nieswandt B: CLP36 Is a Negative Regulator of Glycoprotein VI Signaling in Platelets. Circ Res. 2012, 111: 1410-1420. 10.1161/CIRCRESAHA.112.264754.CrossRefPubMed Gupta S, Braun A, Morowski M, Premsler T, Bender M, Nagy Z, Sickmann A, Hermanns HM, Bosl M, Nieswandt B: CLP36 Is a Negative Regulator of Glycoprotein VI Signaling in Platelets. Circ Res. 2012, 111: 1410-1420. 10.1161/CIRCRESAHA.112.264754.CrossRefPubMed
36.
go back to reference Kim-Kaneyama JR, Miyauchi A, Lei XF, Arita S, Mino T, Takeda N, Kou K, Eto K, Yoshida T, Miyazaki T, et al: Identification of Hic-5 as a novel regulatory factor for integrin alphaIIbbeta3 activation and platelet aggregation in mice. J Thromb Haemost. 2012, 10: 1867-1874. 10.1111/j.1538-7836.2012.04856.x.CrossRefPubMed Kim-Kaneyama JR, Miyauchi A, Lei XF, Arita S, Mino T, Takeda N, Kou K, Eto K, Yoshida T, Miyazaki T, et al: Identification of Hic-5 as a novel regulatory factor for integrin alphaIIbbeta3 activation and platelet aggregation in mice. J Thromb Haemost. 2012, 10: 1867-1874. 10.1111/j.1538-7836.2012.04856.x.CrossRefPubMed
37.
go back to reference Chew V, Lam KP: Leupaxin negatively regulates B cell receptor signaling. J Biol Chem. 2007, 282: 27181-27191. 10.1074/jbc.M704625200.CrossRefPubMed Chew V, Lam KP: Leupaxin negatively regulates B cell receptor signaling. J Biol Chem. 2007, 282: 27181-27191. 10.1074/jbc.M704625200.CrossRefPubMed
Metadata
Title
Paxillin is an intrinsic negative regulator of platelet activation in mice
Authors
Asuka Sakata
Tsukasa Ohmori
Satoshi Nishimura
Hidenori Suzuki
Seiji Madoiwa
Jun Mimuro
Kazuomi Kario
Yoichi Sakata
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2014
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-12-1

Other articles of this Issue 1/2014

Thrombosis Journal 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine